Multicenter trial about single or combination therapy with tofogliflozin and anagliptin in type 2 diabetic patients
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-jRCTs031180440
- Lead Sponsor
- omura Shosaku
- Brief Summary
Comparisons between group showed no significant differences in many parameters. On the other hand, Comparison within groups at 0 and 48 weeks showed significant changes in many parameters.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 50
1.under treatment by once dialy type DPP-4 inhibitor
2.7.0% < HbA1c < 9.0%
3.BMI > 18.0 kg/m2
4.20 years < age < 95 years
5.written informed concent
1.type 1 diabetes or secondary diabetes
2.contraindication for medicine
3.allergy
4.Use of twice daily type DPP-4 inhibitor, or weekly type DPP-4 inhibitor, or DPP-4 inhibitor related combination drug, or SGLT2 inhibitor, or GLP-1 receptor agonist within 4 weeks.
5.eGFR < 30mL/min/1.73m2
6.AST or ALT > 120IU/L
7.history of appoplexy
8.pregnancy or lactationperiod
9.urinary infection, social disease
10.malignancy
11.inappropriate patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method